Mobile

Treatment of Graves’ Orbitopathy (GO) with ATG-Fresenius: A prospective, randomized, open, controlled phase II study to assess the efficacy and safety of an add-on ATG-Fresenius treatment versus a sta...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005261-35

Treatment of Graves’ Orbitopathy (GO) with ATG-Fresenius: A prospective, randomized, open, controlled phase II study to assess the efficacy and safety of an add-on ATG-Fresenius treatment versus a standard steroid treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to investigate whether add-on treatment of ATG-Fresenius S to standard steroid therapy has a beneficial effect on response to therapy defined as Clinical Activity Score (CAS) and Clinical Severity Score (CSS).

Critère d'inclusion

  • Active and moderate to severe Graves’ Orbitopathy

Liens